Search research articles
Contact Us
Filters
Showing results (41-50 of 63) with videos related to
Page
of 7
Sort By:
Biorxiv : the Preprint Server for Biology
|
September 5, 2025
Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapies
Tam Binh V Bui, Denise M Wolf, Michael C Bruck, et al.
Breast Cancer Research : BCR
|
October 4, 2023
B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer
Tessa G Steenbruggen, Denise M Wolf, Michael J Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2024
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Mark Jesus M Magbanua, Ziad Ahmed, Rosalyn W Sayaman, et al.
Nature Cell Biology
|
June 5, 2019
Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities
Jean-Philippe Coppé, Miki Mori, Bo Pan, et al.
Science Translational Medicine
|
April 22, 2026
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer
Xiaopeng Sun, Andres A Ocampo, Ann Hanna, et al.
NPJ Precision Oncology
|
May 15, 2023
Development and testing of a polygenic risk score for breast cancer aggressiveness
Yiwey Shieh, Jacquelyn Roger, Christina Yau, et al.
Nature Medicine
|
June 27, 2018
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments
Kevin C Barry, Joy Hsu, Miranda L Broz, et al.
Cell
|
April 7, 2018
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
Katherine A Hoadley, Christina Yau, Toshinori Hinoue, et al.
Nature Cancer
|
February 9, 2023
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF<sup>V600E</sup> colorectal tumors
Ana Ruiz-Saenz, Chloe E Atreya, Changjun Wang, et al.
Cell Reports. Medicine
|
November 7, 2024
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer
Michael J Campbell, Denise M Wolf, Christina Yau, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 63) with videos related to
Sort By:
Page
of 7
Biorxiv : the Preprint Server for Biology
|
September 5, 2025
Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapies
Tam Binh V Bui, Denise M Wolf, Michael C Bruck, et al.
Breast Cancer Research : BCR
|
October 4, 2023
B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer
Tessa G Steenbruggen, Denise M Wolf, Michael J Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2024
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Mark Jesus M Magbanua, Ziad Ahmed, Rosalyn W Sayaman, et al.
Nature Cell Biology
|
June 5, 2019
Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities
Jean-Philippe Coppé, Miki Mori, Bo Pan, et al.
Science Translational Medicine
|
April 22, 2026
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer
Xiaopeng Sun, Andres A Ocampo, Ann Hanna, et al.
NPJ Precision Oncology
|
May 15, 2023
Development and testing of a polygenic risk score for breast cancer aggressiveness
Yiwey Shieh, Jacquelyn Roger, Christina Yau, et al.
Nature Medicine
|
June 27, 2018
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments
Kevin C Barry, Joy Hsu, Miranda L Broz, et al.
Cell
|
April 7, 2018
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
Katherine A Hoadley, Christina Yau, Toshinori Hinoue, et al.
Nature Cancer
|
February 9, 2023
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF<sup>V600E</sup> colorectal tumors
Ana Ruiz-Saenz, Chloe E Atreya, Changjun Wang, et al.
Cell Reports. Medicine
|
November 7, 2024
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer
Michael J Campbell, Denise M Wolf, Christina Yau, et al.
Page
of 7